746 related articles for article (PubMed ID: 16038784)
21. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
[TBL] [Abstract][Full Text] [Related]
22. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
23. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.
Cornelissen JJ; van der Holt B; Petersen EJ; Vindelov L; Russel CA; Höglund M; Maertens J; Schouten HC; Braakman E; Steijaert MM; Zijlmans MJ; Slaper-Cortenbach I; Boogaerts MA; Löwenberg B; Verdonck LF
Exp Hematol; 2003 Oct; 31(10):855-64. PubMed ID: 14550800
[TBL] [Abstract][Full Text] [Related]
24. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
26. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
27. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells.
Preijers FW; van Hennik PB; Schattenberg A; Ruijs P; Ploemacher RE; de Witte T
Bone Marrow Transplant; 1999 May; 23(10):1061-70. PubMed ID: 10373074
[TBL] [Abstract][Full Text] [Related]
28. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
29. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
[TBL] [Abstract][Full Text] [Related]
30. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease.
Abrahamsen IW; Sømme S; Heldal D; Egeland T; Kvale D; Tjønnfjord GE
Haematologica; 2005 Jan; 90(1):86-93. PubMed ID: 15642674
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow or peripheral blood as a source of stem cells for allogeneic transplantation.
Bacigalupo A; Frassoni F; Van Lint MT
Haematologica; 2002 Aug; 87(8 Suppl):4-8. PubMed ID: 12412382
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
33. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
[TBL] [Abstract][Full Text] [Related]
34. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
Soiffer RJ; Ritz J
Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
[TBL] [Abstract][Full Text] [Related]
36. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
[TBL] [Abstract][Full Text] [Related]
37. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
Martino R; Rovira M; Carreras E; Solano C; Jorge S; De La Rubia J; Caballero MD; de Oteyza JP; Zuazu J; Moraleda JM; Ojeda E; Ferrá C; Serrano D; De La Cámara R; Urbano-Ispízua A; Brunet S;
Haematologica; 2001 Oct; 86(10):1075-86. PubMed ID: 11602414
[TBL] [Abstract][Full Text] [Related]
38. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
39. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
[TBL] [Abstract][Full Text] [Related]
40. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
